Your browser doesn't support javascript.
loading
Secreted ORF8 is a pathogenic cause of severe Covid-19 and potentially targetable with select NLRP3 inhibitors
Xiaosheng Wu; Michelle K Manske; Gordon Ruan; Taylor L Witter; Kevin E Nowakowski; Jithma P Abeykoon; Xinyi Tang; Yue Yu; Kimberly A. Gwin; Annie Wu; Vanessa Taupin; Vaishali Bhardwaj; Jonas Paludo; Surendra Dasari; Haidong Dong; Stephen M Ansell; Andrew D Badley; Matthew Schellenberg; Thomas E Witzig.
Afiliação
  • Xiaosheng Wu; Hematology Division, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
  • Michelle K Manske; Hematology Division, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
  • Gordon Ruan; Hematology Division, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
  • Taylor L Witter; Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA
  • Kevin E Nowakowski; Hematology Division, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
  • Jithma P Abeykoon; Hematology Division, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
  • Xinyi Tang; Hematology Division, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
  • Yue Yu; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA
  • Kimberly A. Gwin; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
  • Annie Wu; Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA
  • Vanessa Taupin; Electron Microscopy Core, University of California San Diego, La Jolla, CA, USA
  • Vaishali Bhardwaj; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
  • Jonas Paludo; Hematology Division, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
  • Surendra Dasari; Deoartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA
  • Haidong Dong; Department of Immunology, Mayo Clinic, Rochester, Minnsota, USA
  • Stephen M Ansell; Hematology Division, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
  • Andrew D Badley; Division of infectious diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA
  • Matthew Schellenberg; Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA
  • Thomas E Witzig; Hematology Division, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
Preprint em En | PREPRINT-BIORXIV | ID: ppbiorxiv-470978
Artigo de periódico
Um artigo publicado em periódico científico está disponível e provavelmente é baseado neste preprint, por meio do reconhecimento de similaridade realizado por uma máquina. A confirmação humana ainda está pendente.
Ver artigo de periódico
ABSTRACT
COVID-19 is a significant cause of morbidity and mortality in blood cancer patients, especially those on immunosuppressive therapy. Despite extensive research, the specific factor associated with SARS-CoV-2 infection that mediates the life-threatening inflammatory cytokine response in patients with severe COVID-19 remains unidentified. Herein we demonstrate that the virus-encoded Open Reading Frame 8 (ORF8) protein is abundantly secreted as a glycoprotein in vitro and in symptomatic patients with COVID-19. ORF8 specifically binds to the NOD-like receptor family pyrin domain-containing 3 (NLRP3) in CD14+ monocytes to induce a non-canonical inflammasomal response, and a canonical response when the second activation signal is present. Levels of ORF8 protein in the blood correlate with severity and disease-specific mortality in patients with acute SARS-CoV-2 infection. Furthermore, the ORF8-induced inflammasome response was readily inhibited by the NLRP3 inhibitor MCC950 in vitro. Our study identifies a dominant cause of pathogenesis, its underlying mechanism, and a potential new treatment for severe COVID-19. Key pointsO_LISecreted glycoprotein ORF8 induces monocytic pro-inflammatory cytokines involving the activation of the NLPR3 inflammasome pathway. C_LIO_LIORF8 is prognostically present in the blood of symptomatic patients with covid-19 and is targetable with NLRP3 inhibitor MCC-950. C_LI
Licença
cc_by_nc_nd
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint